Goldman Sachs
CYTK icon

Goldman Sachs’s Cytokinetics CYTK Stock Holding History

Goldman Sachs’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82M Buy
+33,100
New +$2.38M ﹤0.01% 4394
2026
Q1 		– Sell
-35,000
Closed -$2.22M – 6583
2025
Q4 		$2.22M Buy
35,000
+5,000
+17% +$311K ﹤0.01% 4495
2025
Q3 		$1.65M Sell
30,000
-9,200
-23% -$379K ﹤0.01% 4643
2025
Q2 		$1.3M Buy
39,200
+30,100
+331% +$1.05M ﹤0.01% 4512
2025
Q1 		$366K Buy
+9,100
New +$418K ﹤0.01% 5368
2024
Q4 		– Sell
-47,500
Closed -$2.51M – 6069
2024
Q3 		$2.51M Sell
47,500
-17,800
-27% -$992K ﹤0.01% 3952
2024
Q2 		$3.54M Buy
65,300
+47,300
+263% +$2.86M ﹤0.01% 3478
2024
Q1 		$1.26M Sell
18,000
-184,100
-91% -$14.2M ﹤0.01% 4189
2023
Q4 		$16.9M Buy
+202,100
New +$7.32M ﹤0.01% 2062
2020
Q4 		– Sell
-107,300
Closed -$2.32M – 5520
2020
Q3 		$2.32M Buy
+107,300
New +$2.51M ﹤0.01% 3458
2016
Q4 		– Sell
-26,800
Closed -$246K – 6917
2016
Q3 		$246K Buy
+26,800
New +$280K ﹤0.01% 5641
2015
Q3 		– Sell
-75,000
Closed -$504K – 7301
2015
Q2 		$504K Hold
75,000
– – ﹤0.01% 5203
2015
Q1 		$509K Sell
75,000
-25,000
-25% -$187K ﹤0.01% 5109
2014
Q4 		$801K Buy
+100,000
New +$429K ﹤0.01% 4818
2014
Q3 		– Sell
-38,200
Closed -$183K – 7138
2014
Q2 		$183K Sell
38,200
-130,100
-77% -$794K ﹤0.01% 6260
2014
Q1 		$1.6M Buy
+168,300
New +$1.52M ﹤0.01% 4196

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's CYTK Position: Q2 2026 in Review

Goldman Sachs reduced its Cytokinetics (CYTK) stake by 20% in Q2 2026, selling an estimated $31.9M and leaving 1,761,588 shares worth $150M. The position accounts for 0.01% of the portfolio, ranked #932.

Goldman Sachs first reported a position in CYTK in Q3 2013 and has held it in 50 quarters since. The position peaked at $151M in Q4 2025. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Goldman Sachs held 1,761,588 shares of Cytokinetics worth $150M as of Q2 2026.
  • Goldman Sachs sold 444,170 Cytokinetics shares in Q2 2026, an estimated $31.9M.
  • Cytokinetics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #932 holding.
  • Goldman Sachs first reported a position in Cytokinetics in Q3 2013 and has held it in 50 quarters since.
  • Goldman Sachs's Cytokinetics position peaked at $151M in Q4 2025.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.